dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Simpson-Yap, Steve |
dc.contributor.author | De Brouwer, Edward |
dc.contributor.author | Kalincik, Tomas |
dc.contributor.author | Rijke, Nick |
dc.contributor.author | Hillert, Jan A. |
dc.contributor.author | Walton, Clare |
dc.contributor.author | Zabalza de Torres, Ana |
dc.contributor.author | Arrambide García, Georgina |
dc.date.accessioned | 2022-03-09T11:57:01Z |
dc.date.available | 2022-03-09T11:57:01Z |
dc.date.issued | 2021-11-09 |
dc.identifier.citation | Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021 Nov 9;97(19):e1870–85. |
dc.identifier.issn | 1526-632X |
dc.identifier.uri | https://hdl.handle.net/11351/7128 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosi múltiple |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. The operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation. The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corp, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish government under the Onderzoeksprogramma Artificiële Intelligentie Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium–Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from the National Health and Medical Research Council (NHMRC; 1129189 and 1140766). |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Neurology;97(19) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Complicacions |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /complications |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.title | Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/WNL.0000000000012753 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /complicaciones |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1212/WNL.0000000000012753 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Simpson-Yap S] Department of Medicine, and Neuroepidemiology Unit, Melbourne School of Population & Global Health, University of Melbourne, Parkville, Australia. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia [De Brouwer E] University of Tasmania, Hobart, Australia. ESAT-STADIUS, KU Leuven, Belgium. [Kalincik T] Department of Neurology, Melbourne MS Centre, Royal Melbourne Hospital, Parkville, Australia. [Rijke N, Walton C] MS International Federation, London, UK. [Hillert JA] Department of Clinical Neuroscience, Swedish MS Registry, Stockholm, Sweden. [Zabalza A, Arrambide G] Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34610987 |
dc.identifier.wos | 000713678100016 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |